INVO FERTILITY INC (IVF) Stock Fundamental Analysis

NASDAQ:IVF • US44984F8077

0.9497 USD
-0.01 (-0.85%)
At close: Feb 27, 2026
0.91 USD
-0.04 (-4.18%)
After Hours: 2/27/2026, 8:11:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IVF. IVF was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IVF have multiple concerns. IVF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • IVF had negative earnings in the past year.
  • In the past year IVF has reported a negative cash flow from operations.
  • In the past 5 years IVF always reported negative net income.
  • IVF had a negative operating cash flow in each of the past 5 years.
IVF Yearly Net Income VS EBIT VS OCF VS FCFIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • IVF has a worse Return On Assets (-155.09%) than 87.57% of its industry peers.
  • IVF has a worse Return On Equity (-499.38%) than 82.16% of its industry peers.
Industry RankSector Rank
ROA -155.09%
ROE -499.38%
ROIC N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVF Yearly ROA, ROE, ROICIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • IVF's Gross Margin of 39.17% is on the low side compared to the rest of the industry. IVF is outperformed by 68.65% of its industry peers.
  • IVF's Gross Margin has declined in the last couple of years.
  • IVF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
IVF Yearly Profit, Operating, Gross MarginsIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • IVF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IVF has been increased compared to 1 year ago.
  • IVF has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IVF has a worse debt to assets ratio.
IVF Yearly Shares OutstandingIVF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5K 10K 15K 20K 25K
IVF Yearly Total Debt VS Total AssetsIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -8.57, we must say that IVF is in the distress zone and has some risk of bankruptcy.
  • IVF has a Altman-Z score of -8.57. This is in the lower half of the industry: IVF underperforms 75.14% of its industry peers.
  • IVF has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • IVF's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. IVF outperforms 50.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -8.57
ROIC/WACCN/A
WACC7.08%
IVF Yearly LT Debt VS Equity VS FCFIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

  • A Current Ratio of 0.12 indicates that IVF may have some problems paying its short term obligations.
  • The Current ratio of IVF (0.12) is worse than 95.68% of its industry peers.
  • A Quick Ratio of 0.10 indicates that IVF may have some problems paying its short term obligations.
  • IVF has a Quick ratio of 0.10. This is amonst the worse of the industry: IVF underperforms 95.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.1
IVF Yearly Current Assets VS Current LiabilitesIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • IVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -808.80%.
  • Looking at the last year, IVF shows a quite strong growth in Revenue. The Revenue has grown by 11.50% in the last year.
  • The Revenue has been growing by 34.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-808.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.06%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.59% on average over the next years. This is quite good.
  • Based on estimates for the next years, IVF will show a quite strong growth in Revenue. The Revenue will grow by 10.00% on average per year.
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5Y13.59%
Revenue Next Year13.23%
Revenue Next 2Y28.14%
Revenue Next 3Y37.4%
Revenue Next 5Y10%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IVF Yearly Revenue VS EstimatesIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5M 10M 15M
IVF Yearly EPS VS EstimatesIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -1K -2K -3K -4K -5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IVF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IVF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVF Price Earnings VS Forward Price EarningsIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVF Per share dataIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600

4.3 Compensation for Growth

  • IVF's earnings are expected to grow with 23.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.17%
EPS Next 3Y23.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IVF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INVO FERTILITY INC

NASDAQ:IVF (2/27/2026, 8:11:59 PM)

After market: 0.91 -0.04 (-4.18%)

0.9497

-0.01 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-17
Earnings (Next)04-28
Inst Owners11.54%
Inst Owner Change-94.94%
Ins Owners0.01%
Ins Owner Change-0.69%
Market Cap2.27M
Revenue(TTM)6.94M
Net Income(TTM)-29.21M
Analysts80
Price Target4.08 (329.61%)
Short Float %15.41%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.08%
Min Revenue beat(2)-3.98%
Max Revenue beat(2)10.15%
Revenue beat(4)3
Avg Revenue beat(4)60.92%
Min Revenue beat(4)-3.98%
Max Revenue beat(4)236.57%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)700%
EPS NQ rev (1m)-1000%
EPS NQ rev (3m)-1000%
EPS NY rev (1m)0%
EPS NY rev (3m)-700%
Revenue NQ rev (1m)2.21%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)2.92%
Revenue NY rev (3m)2.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-644.61
EYN/A
EPS(NY)-23.76
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS2.91
BVpS2.45
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.09%
ROE -499.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.17%
FCFM N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.3%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.1
Altman-Z -8.57
F-Score3
WACC7.08%
ROIC/WACCN/A
Cap/Depr(3y)84.61%
Cap/Depr(5y)530.77%
Cap/Sales(3y)6.25%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-808.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.06%
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5Y13.59%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%
Revenue Next Year13.23%
Revenue Next 2Y28.14%
Revenue Next 3Y37.4%
Revenue Next 5Y10%
EBIT growth 1Y-61.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.93%
OCF growth 3YN/A
OCF growth 5YN/A

INVO FERTILITY INC / IVF FAQ

What is the ChartMill fundamental rating of INVO FERTILITY INC (IVF) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IVF.


What is the valuation status of INVO FERTILITY INC (IVF) stock?

ChartMill assigns a valuation rating of 1 / 10 to INVO FERTILITY INC (IVF). This can be considered as Overvalued.


How profitable is INVO FERTILITY INC (IVF) stock?

INVO FERTILITY INC (IVF) has a profitability rating of 0 / 10.


Can you provide the financial health for IVF stock?

The financial health rating of INVO FERTILITY INC (IVF) is 1 / 10.